← board
INDV
Indivior Inc.distress 3/10 · well-funded / low risk$40.10-1%today-4% from 52w high
Lead: Moderate to Severe Opioid Use Disorder
Revenue
$317M
Liquidity
$202M
Runway
1.8 yrs
Shares 1y
-2%
Price & events
+19.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.9%
1D
-1.2%
1W
+0.4%
1M
+20.9%
3M
+21.6%
6M
+136.6%
1Y
+263.9%
2Y
+280.1%
5Y
+470.8%
All
Overview
- Market Cap
- $4.89B
- Enterprise Value
- $5.20B
- Volume
- 41.97K
- 52 Week Range
- $15.38 – $41.83
- Total Shares
- 121.92M
- Float Shares
- 112.96M
- Short %
- 10.83%
- % Held by Insiders
- 1.97%
- % Held by Institutions
- 109.05%
- RVOL
- 0.02x
- Beta
- 1.15
Pipeline stages · 1 programs
INDV-6001, Suboxone, Sublocade
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-01-21 | Phase 2 | INDV-6001, Suboxone, Sublocade | Moderate to Severe Opioid Use Disorder | 123 | completed |
| 2025-09-29 | Phase 2 | INDV-2000 | Opioid Use Disorder | 300 | completed |
Catalyst news & presentations · 5
- 2026-08-04earningsEarningsEarnings releaseyahoo
- 2026-03-12partnershipIndivior announces launch of proposed offering of convertible senior notes due 2031.SEC 8-K
- late January 2026regulatory submissionFiled (NDA/BLA)Effective date of Scheme; Indivior PLC shares exchanged for IPI shares.SEC 8-K
- January 1, 2026trial initiationsecondaryEntered Phase II of Indivior Action Agenda – AccelerateSEC 8-K
- 2025-06-02withdrawalIndivior announces intention to cancel London Stock Exchange listingSEC 8-K
Approved drugs (7)
- OPVEENALMEFENE HYDROCHLORIDE2023 · Prescription
- PERSERIS KITRISPERIDONE2018 · Discontinued
- SUBLOCADEBUPRENORPHINE2017 · Prescription
- SUBOXONEBUPRENORPHINE HYDROCHLORIDE2010 · Prescription
- SUBUTEXBUPRENORPHINE HYDROCHLORIDE2002 · Discontinued
- SUBOXONEBUPRENORPHINE HYDROCHLORIDE2002 · Discontinued
- BUPRENEXBUPRENORPHINE HYDROCHLORIDE1981 · Discontinued
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $51 (+27% upside) · 6 analysts
- 2026-06-18BarclaysOverweight
- 2026-01-12HC Wainwright & Co.Buy
- 2025-10-31Piper SandlerOverweight
- 2025-10-30HC Wainwright & Co.Buy
- 2025-08-27Craig-HallumBuy
- 2025-08-06HC Wainwright & Co.Buy
Competitors — Moderate to Severe Opioid Use Disorder
- none identified
Recent news
- 2026-07-23Indivior Announces Date and Time for Second Quarter 2026 Financial Results and Conference Call - Quiver Quantitative
- 2026-07-23Indivior Leadership to Host Aug. 4 Webcast After Q2 Results - Stock Titan
- 2026-07-23Indivior to Report Second Quarter 2026 Financial Results and Host Webcast - GlobeNewswire
- 2026-07-21ETFs Investing in Indivior Pharmaceuticals, Inc. Stocks - TradingView
- 2026-07-21Indivior Pharmaceuticals, Inc. (INDV) Stock Analysis: Striking Potential with a 29.94% Upside - DirectorsTalk Interviews
- 2026-07-20Indivior Pharmaceuticals Inc (INDV) Shares Fall 3.5% -- What GF Score of 69 Tells Investors - GuruFocus
- 2026-07-20Indivior Pharmaceuticals Inc (INDV) Shares Fall 3.5% -- What GF Score of 69 Tells Investors - GuruFocus
- 2026-07-16Price to earnings forward of Indivior Pharmaceuticals, Inc. – MUN:E7P - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.